Fri, Aug 1, 2014, 5:35 AM EDT - U.S. Markets open in 3 hrs 55 mins

Recent

% | $
Click the to save as a favorite.

Sangamo Biosciences Inc. Message Board

  • Rob_Cos Rob_Cos Aug 6, 2007 1:08 PM Flag

    SGMO-$17 tgt+upside."Building Toward Break-out" Cant Fitz

    CantFitz Jul 25 SGMO report. $17 target + upside."Building Toward Break-out. Expect significant SA milestone pyt & royalties this yr. Multiple near term, revenue sources. Therapeutic product alliance coming."

    Cantor Fitzgerald

    Company Update
    JULY 25, 2007

    LIFE SCIENCES

    Sangamo Biosciences Inc. (SGMO-$9.65)

    Rating: BUY

    Target Price: $17.00

    2Q:07 EPS In-line � Building Toward Break-out

    o Yesterday, after the market close, Sangamo Biosciences reported EPS of $(0.15) for 2Q:07 in-line with our estimate of $(0.13) for the quarter.


    o During 2Q:07, we think Sangamo made significant progress towards building out its business model � leveraging its enabling ZFP platform technology across multiple industries (pharma, agro, biomanufacturing and research lab) �to develop and commercialize proprietary products that provide near-term revenue with the potential for sustainable top-line and bottom-line growth.


    o We expect Sangamo to end 2007 with about $75 million in cash, following the closing of their offering of approximately 3.28 million shares at $9.15 per share on July 20, 2007, along with the upfront fee and other payments from the recent Sigma-Aldrich alliance to create products for research labs.


    o We anticipate continued agro-product development progress with DowAgrosciences following the generation of specific traits in both maize and canola, including payment of milestones later this year. Further, we expect Sangamo to receive milestone payments and royalties from Sigma-Aldrich later this year.


    o We think the multiple near-term revenue sources, ongoing R&D funding, research grants and recent offering, provide Sangamo with the ongoing funding to move its proprietary therapeutic pipeline forward and we expect the company to execute at least one therapeutic product alliance, plus additional commercial biomanufacturing agreements within the next 12 months. We reiterate our BUY rating.

    FULL REPORT:

    http://www1.investorvillage.com/smbd.asp?mb=1933&mn=527&pt=msg&mid=2722056

    SortNewest  |  Oldest  |  Most Replied Expand all replies
 
SGMO
11.88-0.65(-5.19%)Jul 31 4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.
Tesla Motors, Inc.
NasdaqGSThu, Jul 31, 2014 4:00 PM EDT
eHealth, Inc.
NasdaqGSThu, Jul 31, 2014 3:59 PM EDT